UNSPSC 51294504: Enefexine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JMM46GA2V. European Medicines Agency schedules Enefexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06527MIG. Enefexine generally arises in the molecular formula C13H19N.

The term ENEFEXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) ENEFEXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enefexine under HS 29333999 and SITC 51574. As of Q4 2014, ENEFEXINE remains the US FDA Preferred Term for this commodity. Enefexine bears US NLM identifiers UMLS ID C2348443 and NCI Concept Code C72758. SMILES: N1CCC(CC1)c1ccc(cc1)CC.

UNSPSC 51294504 Enefexine is a Commodity code under which state and local governments procure pharmaceutical products, primarily naloxone and related drug-management systems, along with generic multi-source medications and over-the-counter products through cooperative purchasing arrangements and direct health-agency procurement. Recent solicitations show state and local bodies buying naloxone units for emergency opioid response, safe drug deactivation systems for community health programs, and bulk generic and OTC pharmaceuticals through state pharmacy benefit and cooperative contracting vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). The code reflects activity spanning emergency-response pharmaceuticals at the local level and large-scale generic-drug supply contracts at the state and regional cooperative level.

Geographic activity concentrates in the Southeast (Florida), Texas, and the Upper Midwest (Minnesota and Oregon through MMCAP). Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, requesting vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels; and MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with a March 26, 2026 response deadline and July 1, 2026 contract effectiveness. Vendors on MMCAP contracts must maintain $5 million commercial general liability insurance, certify cGMP and DSCSA compliance, and accept a 3 percent administrative fee on purchases.